iBio Inc (IBIO)
1.99
-0.04
(-1.97%)
USD |
NYAM |
May 03, 16:00
1.96
-0.03
(-1.51%)
After-Hours: 20:00
iBio Research and Development Expense (Annual): 10.33M for June 30, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| June 30, 2023 | 10.33M |
| June 30, 2022 | 9.827M |
| June 30, 2021 | 9.989M |
| June 30, 2020 | 3.573M |
| June 30, 2019 | 5.474M |
| June 30, 2018 | 3.986M |
| June 30, 2017 | 4.117M |
| June 30, 2016 | 3.156M |
| June 30, 2015 | 3.495M |
| Date | Value |
|---|---|
| June 30, 2014 | -0.15M |
| June 30, 2013 | 3.431M |
| June 30, 2012 | 4.981M |
| June 30, 2011 | 3.084M |
| June 30, 2010 | 2.517M |
| June 30, 2009 | 0.7974M |
| June 30, 2008 | 0.55M |
| June 30, 2007 | 0.6732M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
3.573M
Minimum
2020
10.33M
Maximum
2023
7.838M
Average
9.827M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Lixte Biotechnology Holdings Inc | 0.8981M |
| PAVmed Inc | 14.28M |
| Avalo Therapeutics Inc | 13.78M |
| Imunon Inc | 11.29M |
| Ocugen Inc | 39.57M |